Then, upon the systemic administration of the reporter protein T22-GFP-H6 and derived cytotoxic constructs, a precise in vivo biodistribution is observed, with the destruction of CXCR4-overexpressing cancer tissues and metastatic foci in the absence of side toxicities [18]. This evidence concerns the gene CXCR4 and cancer.